Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Findings in Patients With Phenylketonuria Before and After KUVAN Therapy

Completed · Not applicable

Conditions studied: Phenylketonuria

In brief

The aim of this pilot study is to determine if there are any changes in brain glucose metabolism in the gray matter of patients with Phenylketonuria (PKU) and whether administration of Sapropterin (KUVAN) therapy can improve such deficits.

Key facts

Study ID

NCT00986973

Run by

Children's Hospital of Philadelphia

People needed

6

Starts

2010-03-01

Expected to finish

2011-09-01

Last updated by the study team

2015-06-08

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or females over the age of 18 years
• Subject must be able to give independent informed consent
• Girls must have a negative urine pregnancy test and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study.
• Subject must have a confirmed diagnosis of PKU
• Subjects with Phenylalanine (Phe) levels over 10 mg/dL
• Subjects naïve to KUVAN therapy or has not received KUVAN in the 6 months before screening

You may not qualify if…

• Pregnancy
• Cognitive deficits resulting from physical trauma (e.g. subject with history of severe birth trauma).
• Neurologic comorbidities including a history of a stroke or a seizure disorder.
• Laboratory abnormalities that indicate clinically significant hepatic disease Aspartate aminotransferase (AST)> 2.0 times the upper limit of normal, Alanine transaminase (ALT) > 2.0 times the upper limit of normal, Prothrombin Time (PT) > 2.0 times the upper limit of normal, Partial Thromboplastin Time(PTT) > 2.0 times the upper limit of normal
• Subjects using medications such as steroids, insulin and glucagons that may interfere with the results of PET scan.
• Subjects using medications that inhibit folate metabolism such as methotrexate
• Subjects using medications known to affect nitric oxide-mediated vasorelaxation.
• Subjects using Levodopa
• Treatment with KUVAN in the past 6 months before study entry.
• Treatment with any investigational product in the last 90 days before study entry

Where it is running

• Children's Hospital of Philadelphia, Section of Metabolism,PKU program — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.